Butterfly Network Shares Rise 17.3% to $9.01
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Butterfly Network is up 17.3%, or $1.33 to $9.01.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BFLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BFLY
Wall Street analysts forecast BFLY stock price to fall
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.230
Low
4.00
Averages
4.25
High
4.50
Current: 8.230
Low
4.00
Averages
4.25
High
4.50
About BFLY
Butterfly Network, Inc. is a healthcare company focused on medical imaging with its Ultrasound-on-Chip semiconductor technology and ultrasound software solutions. The Company's solution, leveraging its Ultrasound-on-Chip technology, enables the practical application of ultrasound information into the clinical workflow. Its product portfolio includes a combination of hardware and software, including Butterfly iQ3, Butterfly iQ+, Butterfly iQ+ Bladder, and Butterfly iQ+ Vet devices, software subscriptions, and professional services. It offers cloud-based software solutions to healthcare systems, teleguidance, in-app educational tutorials as well as its ScanLab education-only app, formal education programs through its Butterfly Academy software and Butterfly Certified courses, as well as professional services for large scale deployments. Its devices are commercially available to trained healthcare practitioners in areas including, but not limited to, parts of Africa, Asia, and Australia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Chewy's Stock Performance Declines, Investors Find It Hard to Hold
- Chewy's Stock Performance: Chewy's year-to-date stock performance has been disappointing, with investors stating that it is 'too hard to own,' reflecting concerns about its future profitability and potentially leading to decreased investor confidence.
- Butterfly Network's Outlook: Despite not being profitable, Butterfly Network is viewed as a promising investment at $8 per share, indicating market expectations for future growth that may attract risk-seeking investors.
- Nextpower's Investment Review: Nextpower's founder, Dan Shugar, is referred to as a 'miracle worker,' and while investors acknowledge their mistake in selling early, the positive outlook for the company may draw more investor interest.
- Preformed Line Products' Prospects: Preformed Line Products is compared to a 'mini Quanta Services,' with optimistic market sentiment about its growth potential, and if communities cease to reject data center constructions, its stock price could rise further.
See More
Butterfly Network Executive Sells Nearly 400K Shares
- Executive Share Sale: Butterfly Network's Chief Business Officer Steve Cashman disclosed the sale of 399,461 shares on June 5 and 8, 2026, totaling approximately $1.89 million, representing 19.68% of his direct holdings, indicating a cautious outlook on the company's future.
- Transaction Price Analysis: The weighted average sale price was $4.74 per share, while the market close on June 8, 2026, was $4.78, suggesting Cashman sold at a relatively high point, potentially reflecting concerns about future stock price movements.
- Revenue Growth Overview: Despite Butterfly Network achieving a 19% revenue growth in 2025 and 25% in Q1 2026, these figures do not fully account for the stock's volatility, highlighting market uncertainty regarding the company's future trajectory.
- Impact of Licensing Agreement: The licensing deal with Midjourney provides Butterfly with a minimum annual fee of $10 million and milestone payments up to $9 million, which, while significant, introduces customer concentration risk that could affect future growth stability.
See More
Butterfly Network Executive Sells 399,461 Shares in Major Transaction
- Executive Stock Sale: Butterfly Network's Chief Business Officer Steve Cashman disclosed the direct sale of 399,461 shares of Common Stock on June 5 and 8 for approximately $1.89 million, indicating a potential lack of confidence in the company's future prospects.
- Largest Single Transaction: This sale marks Cashman's largest open-market transaction to date, surpassing his previous maximum of 250,000 shares sold on February 26, 2026, suggesting that his decisions may be influenced by market volatility.
- Change in Ownership Proportion: The sale represented 19.68% of his direct holdings, leaving him with 1,630,407 shares post-transaction, which indicates his continued significant position in the company but raises questions about his future intentions regarding ownership.
- Market Reaction and Risks: Despite Butterfly Network's revenue growth of 19% in 2025 and 25% in Q1 2026, there are doubts about whether the stock's rapid rise reflects genuine business improvement, particularly given the concentration risk associated with its licensing deal with Midjourney, which could impact future growth potential.
See More
Butterfly Network Executive Sells 399K Shares
- Executive Sell-off Scale: Butterfly Network's Chief Business Officer Steve Cashman disclosed the direct sale of 399,461 shares of common stock on June 5 and 8, 2026, totaling approximately $1.89 million, marking his largest single open-market sale to date, exceeding his previous maximum of 250,000 shares, indicating a cautious outlook on the company's future.
- Shareholding Proportion Change: This sale represented 19.68% of Cashman's direct holdings, leaving him with 1,630,407 shares post-transaction, suggesting that despite the sell-off, he maintains a significant stake in the company, which could influence market confidence.
- Market Reaction Analysis: Although Butterfly Network's revenue grew by 19% in 2025 and 25% in Q1 2026, the market's rapid price increase raises concerns, as a significant portion of future revenue is tied to a licensing deal with Midjourney, presenting a concentration risk for investors.
- Investor Strategy Recommendation: Analysts advise investors to exercise patience when considering Butterfly Network stock, especially given the stable performance of its core ultrasound business, as the sustainability of recent licensing revenue remains to be seen amid the stock's recent price surge.
See More
Butterfly Launches Handheld Ultrasound Devices in Brazil
- Market Expansion: Butterfly Network's launch of its handheld ultrasound devices iQ+ and iQ3 in Brazil marks a significant step in its international growth strategy, as Brazil represents the largest medical device market in Latin America with substantial market potential.
- Technological Advantage: By successfully meeting Brazil's regulatory and certification requirements, Butterfly demonstrates the strength of its ultrasound technology, providing reliable solutions for clinicians in high-standard markets, thereby enhancing its competitive edge.
- Improved Accessibility: The introduction of these devices not only increases diagnostic capacity in high-volume hospitals and emergency settings but also improves healthcare access in underserved rural communities, enabling more patients to receive timely medical imaging.
- Global Footprint Expansion: The commercial launch in Brazil further extends Butterfly's global market presence, supporting its mission to increase access to its technology in key international markets and advance the democratization of medical imaging.
See More
Jim Cramer Endorses Medline as Best IPO of the Year
- IPO Outlook: Jim Cramer identifies Medline as the best IPO of the year, indicating strong market confidence in its future performance, which may attract more investor interest.
- Investment Recommendation: Cramer explicitly endorses Medline on his show, emphasizing its investment value, which could drive stock price increases and bolster market confidence.
- Positive Market Reaction: Medline's performance gains recognition from Cramer, potentially prompting more analysts to focus on it and provide favorable evaluations, thereby enhancing its market position.
- Risk and Opportunity: While Cramer mentions Nuscale Power as speculative, his positive view on Medline highlights its relative safety in the current market environment, appealing to risk-averse investors.
See More
Chewy's Stock Performance Declines, Investors Find It Hard to Hold
- Chewy's Stock Performance: Chewy's year-to-date stock performance has been disappointing, with investors stating that it is 'too hard to own,' reflecting concerns about its future profitability and potentially leading to decreased investor confidence.
- Butterfly Network's Outlook: Despite not being profitable, Butterfly Network is viewed as a promising investment at $8 per share, indicating market expectations for future growth that may attract risk-seeking investors.
- Nextpower's Investment Review: Nextpower's founder, Dan Shugar, is referred to as a 'miracle worker,' and while investors acknowledge their mistake in selling early, the positive outlook for the company may draw more investor interest.
- Preformed Line Products' Prospects: Preformed Line Products is compared to a 'mini Quanta Services,' with optimistic market sentiment about its growth potential, and if communities cease to reject data center constructions, its stock price could rise further.
See More
Butterfly Network Executive Sells Nearly 400K Shares
- Executive Share Sale: Butterfly Network's Chief Business Officer Steve Cashman disclosed the sale of 399,461 shares on June 5 and 8, 2026, totaling approximately $1.89 million, representing 19.68% of his direct holdings, indicating a cautious outlook on the company's future.
- Transaction Price Analysis: The weighted average sale price was $4.74 per share, while the market close on June 8, 2026, was $4.78, suggesting Cashman sold at a relatively high point, potentially reflecting concerns about future stock price movements.
- Revenue Growth Overview: Despite Butterfly Network achieving a 19% revenue growth in 2025 and 25% in Q1 2026, these figures do not fully account for the stock's volatility, highlighting market uncertainty regarding the company's future trajectory.
- Impact of Licensing Agreement: The licensing deal with Midjourney provides Butterfly with a minimum annual fee of $10 million and milestone payments up to $9 million, which, while significant, introduces customer concentration risk that could affect future growth stability.
See More
Butterfly Network Executive Sells 399,461 Shares in Major Transaction
- Executive Stock Sale: Butterfly Network's Chief Business Officer Steve Cashman disclosed the direct sale of 399,461 shares of Common Stock on June 5 and 8 for approximately $1.89 million, indicating a potential lack of confidence in the company's future prospects.
- Largest Single Transaction: This sale marks Cashman's largest open-market transaction to date, surpassing his previous maximum of 250,000 shares sold on February 26, 2026, suggesting that his decisions may be influenced by market volatility.
- Change in Ownership Proportion: The sale represented 19.68% of his direct holdings, leaving him with 1,630,407 shares post-transaction, which indicates his continued significant position in the company but raises questions about his future intentions regarding ownership.
- Market Reaction and Risks: Despite Butterfly Network's revenue growth of 19% in 2025 and 25% in Q1 2026, there are doubts about whether the stock's rapid rise reflects genuine business improvement, particularly given the concentration risk associated with its licensing deal with Midjourney, which could impact future growth potential.
See More
Butterfly Network Executive Sells 399K Shares
- Executive Sell-off Scale: Butterfly Network's Chief Business Officer Steve Cashman disclosed the direct sale of 399,461 shares of common stock on June 5 and 8, 2026, totaling approximately $1.89 million, marking his largest single open-market sale to date, exceeding his previous maximum of 250,000 shares, indicating a cautious outlook on the company's future.
- Shareholding Proportion Change: This sale represented 19.68% of Cashman's direct holdings, leaving him with 1,630,407 shares post-transaction, suggesting that despite the sell-off, he maintains a significant stake in the company, which could influence market confidence.
- Market Reaction Analysis: Although Butterfly Network's revenue grew by 19% in 2025 and 25% in Q1 2026, the market's rapid price increase raises concerns, as a significant portion of future revenue is tied to a licensing deal with Midjourney, presenting a concentration risk for investors.
- Investor Strategy Recommendation: Analysts advise investors to exercise patience when considering Butterfly Network stock, especially given the stable performance of its core ultrasound business, as the sustainability of recent licensing revenue remains to be seen amid the stock's recent price surge.
See More
Butterfly Launches Handheld Ultrasound Devices in Brazil
- Market Expansion: Butterfly Network's launch of its handheld ultrasound devices iQ+ and iQ3 in Brazil marks a significant step in its international growth strategy, as Brazil represents the largest medical device market in Latin America with substantial market potential.
- Technological Advantage: By successfully meeting Brazil's regulatory and certification requirements, Butterfly demonstrates the strength of its ultrasound technology, providing reliable solutions for clinicians in high-standard markets, thereby enhancing its competitive edge.
- Improved Accessibility: The introduction of these devices not only increases diagnostic capacity in high-volume hospitals and emergency settings but also improves healthcare access in underserved rural communities, enabling more patients to receive timely medical imaging.
- Global Footprint Expansion: The commercial launch in Brazil further extends Butterfly's global market presence, supporting its mission to increase access to its technology in key international markets and advance the democratization of medical imaging.
See More
Jim Cramer Endorses Medline as Best IPO of the Year
- IPO Outlook: Jim Cramer identifies Medline as the best IPO of the year, indicating strong market confidence in its future performance, which may attract more investor interest.
- Investment Recommendation: Cramer explicitly endorses Medline on his show, emphasizing its investment value, which could drive stock price increases and bolster market confidence.
- Positive Market Reaction: Medline's performance gains recognition from Cramer, potentially prompting more analysts to focus on it and provide favorable evaluations, thereby enhancing its market position.
- Risk and Opportunity: While Cramer mentions Nuscale Power as speculative, his positive view on Medline highlights its relative safety in the current market environment, appealing to risk-averse investors.
See More
